Evidence map›Paper›PMID 42470473›Full record

ArticleMolecular biology reports2026

Increased MYB alternative promoter usage induces daunorubicin resistance in human leukemia cells via ABCA2 upregulation.

Huiying Fang, Yucheng Wang, Zhenhua Zhou, Xinyu Li, Chang Sun, Junfang Zhang, Bingshe Han

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Huiying FangKey Laboratory of Exploration and Utilization of Aquatic Genetic Resources, Ministry of Education, College of Fisheries and Life Science, Shanghai Ocean University, Shanghai, 201306, China.
Yucheng WangKey Laboratory of Exploration and Utilization of Aquatic Genetic Resources, Ministry of Education, College of Fisheries and Life Science, Shanghai Ocean University, Shanghai, 201306, China.
Zhenhua ZhouKey Laboratory of Exploration and Utilization of Aquatic Genetic Resources, Ministry of Education, College of Fisheries and Life Science, Shanghai Ocean University, Shanghai, 201306, China.
Xinyu LiKey Laboratory of Exploration and Utilization of Aquatic Genetic Resources, Ministry of Education, College of Fisheries and Life Science, Shanghai Ocean University, Shanghai, 201306, China.
Chang SunKey Laboratory of Exploration and Utilization of Aquatic Genetic Resources, Ministry of Education, College of Fisheries and Life Science, Shanghai Ocean University, Shanghai, 201306, China.
Junfang ZhangKey Laboratory of Exploration and Utilization of Aquatic Genetic Resources, Ministry of Education, College of Fisheries and Life Science, Shanghai Ocean University, Shanghai, 201306, China. jfzhang@shou.edu.cn.
Bingshe HanKey Laboratory of Exploration and Utilization of Aquatic Genetic Resources, Ministry of Education, College of Fisheries and Life Science, Shanghai Ocean University, Shanghai, 201306, China. bs-han@shou.edu.cn.ORCID https://orcid.org/0000-0001-8618-3570

Funding

the National Natural Science Foundation of China No. 81770165
6 · The paper itself

Abstract

backgroundMYB is a key transcriptional regulator of hematopoietic cell proliferation, survival, and lineage commitment. Aberrant MYB activity has been linked to hematologic malignancies and clinically relevant features, including poor prognosis and drug resistance. However, the mechanisms by which MYB contributes to drug resistance in leukemia remain unclear. METHODS AND

resultsHere, we show that altered MYB alternative promoter usage may contribute to DNR resistance in leukemia cells, at least in part through ABCA2 upregulation. CCK8 assays showed that ΔN MYB promoted leukemia cell proliferation and enhanced DNR resistance more potently than full-length MYB. RT-qPCR showed that both full-length MYB and ΔN MYB up-regulated ABC transporter genes, with ΔN MYB exerting a stronger effect than full-length MYB and ABCA2 showing the most pronounced increase. RT-qPCR analysis of DNR-resistant leukemia cells showed no obvious change in total MYB expression and MYB exon 2 level, whereas MYB exon 1 level was decreased, the MYB exon 2/exon 1 ratio and ABCA2 expression were markedly increased. Rescue experiments showed that ABCA2 knockdown partially reversed the proliferation-promoting and DNR-resistant effects of ΔN MYB in leukemia cells.

conclusionsThese findings suggest that increased MYB TSS2-associated transcription contributes to DNR resistance in human leukemia cells, potentially through ΔN MYB-associated ABCA2 upregulation. This pathway may represent a potential therapeutic target for overcoming DNR resistance in leukemia.

Indexed as

ATP-Binding Cassette TransportersDaunorubicinDrug Resistance, NeoplasmLeukemiaProto-Oncogene Proteins c-mybCell Line, TumorCell ProliferationGene Expression Regulation, LeukemicHumansPromoter Regions, GeneticUp-RegulationABCA2 protein, humanATP-Binding Cassette TransportersDaunorubicinMYB protein, humanProto-Oncogene Proteins c-mybABCA2Drug ResistanceLeukemiaMYBTSS2

Identifiers

PMID42470473

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.